Presentation is loading. Please wait.

Presentation is loading. Please wait.

DCB for In-Stent Restenosis: Is It Superior to DES?

Published byDerek Richards Modified over 5 years ago

Similar presentations

Presentation on theme: "DCB for In-Stent Restenosis: Is It Superior to DES?"— Presentation transcript:

1 DCB for In-Stent Restenosis: Is It Superior to DES?
Robert A. Byrne MB BCh PhD FESC CRT, Washington, D.C. | 20th February 2017

2 Disclosures Lecture fees:
B. Braun Melsungen, Biotronik, Boston Scientific Institutional research grants: Boston Scientific, Heartflow

3 Is DCB Superior to DES for In-Stent Restenosis?
Agenda Is DCB Superior to DES for In-Stent Restenosis? Device selection overview BMS in-stent restenosis DES in-stent restenosis Take home message Byrne, R.A. | CRT Washington, D.C. | 20th February 2017

4 Vascular Brachytherapy Cutting/Scoring Balloon
ISR: Device Selection Plain Balloon PTCA Vascular Brachytherapy Cutting/Scoring Balloon Atherectomy Drug-Coated Balloon Drug-Eluting Stent

5 ISR Network Meta-analysis
Rankogram of PCI strategies for any type of ISR for %DS, binary restenosis, and TLR Siontis et al. | Lancet 2015

6 Is DCB Superior to DES for In-Stent Restenosis?
Agenda Is DCB Superior to DES for In-Stent Restenosis? Device selection overview BMS in-stent restenosis DES in-stent restenosis Take home message Byrne, R.A. | CRT Washington, D.C. | 20th February 2017

7 The more you gain, the more you lose!
Endpoints: DCB vs DES Achtung! When comparing balloons against stents late loss is not a valid angiographic endpoint The more you gain, the more you lose! Siontis et al. | Lancet 2015

8 PEPCAD II ISR Study: Results
BMS-ISR: DCB vs DES PEPCAD II ISR Study: Results Late Loss Minimal Lumen Diameter Unvedorben et al. Circulation 2009

9 BMS-ISR: DCB vs G2 DES - RIBS V Primary Endpoint: MLD at FU
MLD-FU DCB EES p < 2.36 2.01 (mm) In-Segment Seg Lesion MLD-FU (mm) p < 2.44 2.03 In-Lesion Alfonso et al. JACC 2014

10 TIS Trial: BMS In-stent Restenosis
DCB is Superior to DES…or is it? The starting position was not the same! Pleva et al. | Circ Cardiovasc Interv. 2016

11 Is DCB Superior to DES for In-Stent Restenosis?
Agenda Is DCB Superior to DES for In-Stent Restenosis? Device selection overview BMS in-stent restenosis DES in-stent restenosis Take home message Byrne, R.A. | CRT Washington, D.C. | 20th February 2017

12 DES-ISR: DCB v DES v Angioplasty
Diameter Stenosis at Follow-up Angiography 100 Paclitaxel-Eluting Balloon (PEB) Paclitaxel-Eluting Stent (PES) 80 Balloon Angioplasty (BA) 60 PEB versus BA PES versus BA Psuperiority <0.001 PEB 38.0% Cumulative Frequency (%) 40 PES 37.4% BA 54.1% 20 PEB versus PES Pnon-inferiority =0.007 20 40 60 80 100 Diameter Stenosis at Follow-up Angiography (%) ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches; Byrne et al. Lancet 2013

13 DCB for in-stent restenosis
the comparable performance of DCB and repeat stenting with DES is important: by obviating the need for additional stent implantation, DCB therapy may be the preferred treatment option for this indication

14 DES-ISR: DCB Angioplasty Open question after ISAR-DESIRE 3
Comparative efficacy data versus newer generation DES Incremental value of scoring balloon pre-dilation Long-term outcome data from patients treated for DES-restenosis

15 DES-ISR: DCB Angioplasty Open question after ISAR-DESIRE 3
Comparative efficacy data versus newer generation DES Incremental value of scoring balloon pre-dilation Long-term outcome data from patients treated for DES-restenosis

16 RIBS-IV: DES-ISR: DCB v G2 DES
QCA: MLD at FU Alfonso et al. JACC 2015 MLD-FU EES DEB p = 0.004 (mm) 2,5 2 2.03 1,5 1.80 1 In-Segment (Primary Endpoint) 0,5 Seg Lesion MLD-FU (mm) p < 0.001 2,5 2 2.20 1.89 1,5 1 In-Lesion 0,5

17 DES-ISR: DCB Angioplasty Open question after ISAR-DESIRE 3
Comparative efficacy data versus newer generation DES Incremental value of scoring balloon pre-dilation Long-term outcome data from patients treated for DES-restenosis

18 ISAR-DESIE 4: Primary Endpoint
Diameter Stenosis at Follow-up Angiography 100 Scoring-balloon 80 Control P= 0.047 60 Cumulative Frequency (%) 40 40.4% ± 21.4 20 35.0% ± 16.8 20 40 60 80 100 Diameter Stenosis at Follow-up Angiography (%) ISAR-DESIRE 4: Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4

19 DES-ISR: DCB Angioplasty Open question after ISAR-DESIRE 3
Comparative efficacy data versus newer generation DES Incremental value of scoring balloon pre-dilation Long-term outcome data from patients treated for DES-restenosis

20 ISAR-DESIRE 3: Results at 3 years
TLR TLR Death/MI Death/MI ISAR-DESIRE 3 | Kufner et al. | JACC Interv 2015

21 Key question Is this degree of decrement in antirestenotic efficacy allowable in order that additional stent implantation might be avoided?

22 Upcoming data

23 Prospective, multicenter, single arm
ISAR-DESIRE 3A (Intracoronary Stenting and Angiographic Results: Drug Eluting Stent In-Stent Restenosis: 3A) ISAR-DESIRE 3A Prospective, multicenter, single arm n = 125 pts Enrollment & Follow-Up 1 Y Population: N= 125 patients with symptoms and/or objective signs of ischemia present and Restenosis at the site of previous limus-analogue DES implantation. Historical-control trial comparing to conventional paclitaxel-coated balloon with iopromide excipient (SeQuent Please PCB, B. Braun; data from ISAR-DESIRE 3) Primary Outcome: In-segment percent diameter stenosis (%DS) at 6-8 month follow-up angiography Principal investigators: Deutsches Herzzentrum München: Dr. Robert Byrne, Prof. Adnan Kastrati Klinikum Landshut: Prof. Bernard Zrenner

24 Is DCB Superior to DES for In-Stent Restenosis?
Take Home Message Is DCB Superior to DES for In-Stent Restenosis? Two strategies should be considered: PCI with EES because of the best angiographic and clinical outcomes, and DCB because of its ability to provide favourable results without adding a new stent layer At DHZ if the mechanical integrity of the stent is preserved, DCB is the default strategy Siontis et al. | Lancet 2015

25 Thank you for your attention!

26 Thank you for your attention!
Robert A. Byrne MB BCh PhD FESC

27 SCAAR data shows promising outcomes for Pantera Lux vs key competitors
Lagerqvist, oral presentation, TCT 2013

28 Target Lesion Revascularization
Secondary Endpoint Binary Restenosis Target Lesion Revascularization P =0.03 P = 0.25 % % Scoring balloon Control Scoring balloon Control ISAR-DESIRE 4: Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 36

Download ppt "DCB for In-Stent Restenosis: Is It Superior to DES?"

Similar presentations

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.

M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
Advanced Angioplasty 2008 London 23.1.-25.1.2008 Sequent Paclitaxel-Elutng Balloon Scientific Program Wolfgang Bocksch,M.D.,PhD. Director Cardiac Catheterization.

Advanced Angioplasty 2008 London Sequent Paclitaxel-Elutng Balloon Scientific Program Wolfgang Bocksch,M.D.,PhD. Director Cardiac Catheterization.
A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With Coronary In-Stent Restenosis of Drug-

A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With Coronary In-Stent Restenosis of Drug-
M.Unverdorben; TCT 2007 1 Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.

M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.

As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,

Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,
Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.

Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.

Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.

Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
Neointimal Modification with Scoring-Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug- Eluting Coronary Stents Deutsches.

Neointimal Modification with Scoring-Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug- Eluting Coronary Stents Deutsches.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.

Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.

Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität Munich, Germany A Polymer-Free Dual Drug-Eluting.

Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität Munich, Germany A Polymer-Free Dual Drug-Eluting.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

Similar presentations

Ads by Google